SE8303913D0 - Heterocyclic Associations - Google Patents

Heterocyclic Associations

Info

Publication number
SE8303913D0
SE8303913D0 SE8303913A SE8303913A SE8303913D0 SE 8303913 D0 SE8303913 D0 SE 8303913D0 SE 8303913 A SE8303913 A SE 8303913A SE 8303913 A SE8303913 A SE 8303913A SE 8303913 D0 SE8303913 D0 SE 8303913D0
Authority
SE
Sweden
Prior art keywords
alkyl
represents hydrogen
cycloalkyl
hydroxy
substituted
Prior art date
Application number
SE8303913A
Other languages
Swedish (sv)
Other versions
SE8303913L (en
Inventor
B J Price
R Hayes
D E Bays
J Wilson
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SE8303913D0 publication Critical patent/SE8303913D0/en
Publication of SE8303913L publication Critical patent/SE8303913L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The invention relates to compounds of the general formula (I> <IMAGE> and physiologically acceptable salts, solvates and hydrates thereof, in which R1 represents hydrogen, C1-14 alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, trifluoroalkyl, heteroaralkyl or alkyl substituted by cycloalkyl, hydroxy, alkoxy, amino, alkylamino or dialkylamino; and R2 represents hydrogen or a C1-4 alkyl group; or R1 and R2 together with the nitrogen atom to which they are attached form a 5 to 10 membered ring which may be saturated or may contain at least one double bond, may be unsubstituted or may be substituted by one or more C1-3 alkyl groups or a hydroxy group and/or may contain another heteroatom selected from oxygen or sulphur; Alk represents a straight or branched alkylene chain or 1 to 3 carbon atoms; Q represents a benzene ring in which incorporation into the rest of the molecule is through bonds at the 1- and 3- or 1- and 4-positions; R5 represents hydrogen or acyl; n and m, which may be the same or different, are each 1 or 2; R3 represents hydrogen or alkyl; R4 represents hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, phenyl, pyridyl, aralkyl, heteroaralkyl or alkyl substituted by hydroxy, C1-3 alkoxy, amino C1-3 alkylamino or C1-3 dialkylamino, or R3 and R4 together with the nitrogen atom to which they are attached form a 5-7 membered ring which may contain another heteroatom; and r represents an integer which is 1 or 2. The compounds of formula (I) show biological activity as selective histamine H2-antagonists.
SE8303913A 1982-07-08 1983-07-08 Heterocyclic Associations SE8303913L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8219746 1982-07-08

Publications (2)

Publication Number Publication Date
SE8303913D0 true SE8303913D0 (en) 1983-07-08
SE8303913L SE8303913L (en) 1984-01-09

Family

ID=10531541

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8303913A SE8303913L (en) 1982-07-08 1983-07-08 Heterocyclic Associations

Country Status (11)

Country Link
JP (1) JPS5927880A (en)
AU (1) AU1666583A (en)
BE (1) BE897247A (en)
DE (1) DE3324771A1 (en)
DK (1) DK317283A (en)
FR (1) FR2532937A1 (en)
GB (1) GB2124622A (en)
IT (1) IT8348653A0 (en)
NL (1) NL8302450A (en)
SE (1) SE8303913L (en)
ZA (1) ZA835009B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567191A (en) * 1983-06-07 1986-01-28 Merck & Co., Inc. Amino-phenyl-thiadiazoledioxides as gastric secretion inhibitors
DE3326545A1 (en) * 1983-07-22 1985-01-31 Ludwig Heumann & Co GmbH, 8500 Nürnberg PROPAN-2-OL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
DE3408327A1 (en) * 1984-03-07 1985-09-12 Ludwig Heumann & Co GmbH, 8500 Nürnberg DIAMOND DERIVATIVES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
CN1720240B (en) 2002-10-09 2010-10-27 先灵公司 Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
US7338968B2 (en) 2003-12-19 2008-03-04 Schering Corporation Thiadiazoles AS CXC- and CC- chemokine receptor ligands
WO2005068460A1 (en) 2003-12-22 2005-07-28 Schering Corporation Isothiazole dioxides as cxc- and cc- chemokine receptor ligands
CA2613428A1 (en) 2005-06-29 2007-01-11 Schering Corporation 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
JP2009500334A (en) 2005-06-29 2009-01-08 シェーリング コーポレイション Disubstituted oxadiazoles as CXC-chemokine receptor ligands
EP4196793A1 (en) 2020-08-11 2023-06-21 Université de Strasbourg H2 blockers targeting liver macrophages for the prevention and treatment of liver disease and cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040696B1 (en) * 1980-04-30 1986-08-27 Merck & Co. Inc. Aminothiadiazoles as gastric secretion inhibitors
US4411899A (en) * 1981-12-21 1983-10-25 Merck & Co., Inc. Substituted derivatives of amino alkane diols as gastric secretion inhibitors

Also Published As

Publication number Publication date
SE8303913L (en) 1984-01-09
FR2532937A1 (en) 1984-03-16
NL8302450A (en) 1984-02-01
ZA835009B (en) 1985-02-27
AU1666583A (en) 1984-01-12
DE3324771A1 (en) 1984-01-12
IT8348653A0 (en) 1983-07-08
JPS5927880A (en) 1984-02-14
GB8318525D0 (en) 1983-08-10
DK317283A (en) 1984-01-09
DK317283D0 (en) 1983-07-08
GB2124622A (en) 1984-02-22
BE897247A (en) 1984-01-09

Similar Documents

Publication Publication Date Title
SE8406200D0 (en) indole derivatives
NO901392D0 (en) IMMUNO MODULATING AZASPIRANS.
FR2663633B1 (en) NEW CHALCONES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FI894061A0 (en) Process for the preparation of disubstituted N-cycloalkylalkylbenzylamines useful as medicaments and their synthetic intermediates
ATE49592T1 (en) 6-OXYGENATED-1,3,4,5TETRAHYDROBENZ(CD)INDOLE-4-AMINES.
PT83725B (en) METHOD FOR PREPARING NEW 3-OXADIOL-BETA-CARBOLINE AND 3-CARBOXYLATE-BETA-CARBOLINE DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
SE8303913D0 (en) Heterocyclic Associations
MX9301045A (en) PROCEDURE FOR PREPARING FIBRINOGEN RECEIVING ANTAGONISTS.
ES2057802T3 (en) NEW DERIVATIVES OF 3-AMINO-CHROMAN, PREPARATION PROCEDURE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ATE83234T1 (en) OXADIAZOLE PYRIMIDINONES, THEIR PRODUCTION AND COSMETIC AND DERMOPHARMACEUTICAL USE.
ATE69220T1 (en) SIX-MEMBERED HETEROCYCLIC DERIVATIVES OF N&#39;SUBSTITUTEN,N&#39;-DIACYLHYDRAZINES.
ES8301969A1 (en) 5-Amino-tetrazole derivatives, processes for their preparation and pharmaceutical compositions containing them.
FI845095L (en) AMINOIMIDAZOLONE DERIVATIVES SAOSOM HISTAMINE-H2 ANTAGONISTER.
FI813437L (en) BIOLOGICALLY ACTIVE THICYCLIC AMINES, METHODS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREFOR
IL71503A0 (en) Disubstituted polymethylene imines,their preparation and pharmaceutical compositions containing them
ES556048A0 (en) A PROCEDURE FOR THE PREPARATION OF A THIAZOLIDINE DERIVATIVE.
GR3007498T3 (en)
ATE11413T1 (en) AMINOALKYLBENZOFURAN DERIVATIVES, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM.
SE8301039L (en) HETEROCYCLIC DERIVATIVES
SE8802162L (en) NEW AMINOACYLATES OF GLYCEROL ACETAL
ATE22683T1 (en) SUBSTITUTE HETEROCYCLYLPHENYLSULPHONYL AND PHOSPHONYLAMIDINE, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL APPLICATION.
ATE44741T1 (en) 2-(N-SUBSTITUTED GUANIDINO)-4HETEROARYLTHIAZOLE AS ANTI-ULCER AGENTS.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8303913-1

Effective date: 19860716

Format of ref document f/p: F